



## Agreement at a value of 16 MSEK signed between C-RAD and customer in North Rhine-Westphalia, Germany

**C-RAD is re-confirmed as a partner for outstanding radiotherapy by a clinic in North Rhine-Westphalia, Germany.**

A C-RAD customer in North Rhine-Westphalia, Germany decides to expand the existing SGRT solution with additional Catalyst systems.

The order, which has a value, before taxes, of approximately 16 MSEK for C-RAD, includes the complete software suite, including modules for Respiratory Gating, Patient Setup & Positioning, and Motion Monitoring. A service contract for several systems is also included. Delivery and installation are expected to commence before the end of the year. After complete implementation of the order, our customer will be able to use the new Catalyst+HD (3 camera systems) on two C-arm therapy systems and on another two new therapy systems with ring geometry to the advantage of their own workflow and for the patients.

"We are thrilled about the re-confirmation of our strong cooperation. Thus, the use of our SGRT system solution will become the standard in the state-of-the-art radiotherapy at this location" said Cecilia de Leeuw, CEO and President of C-RAD AB.

### For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, [investors@c-rad.com](mailto:investors@c-rad.com)

Christoffer Herou, CFO, +46 (0)725 82 86 16, [investors@c-rad.com](mailto:investors@c-rad.com)

### About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Press Release  
29 September 2023 13:09:00 CEST



*This information is information that C-RAD is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-29 13:09 CEST.*

#### **Attachments**

[Agreement at a value of 16 MSEK signed between C-RAD and customer in North Rhine-Westphalia, Germany](#)